X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding is intended to aid Entos in advancing a personalized immunotherapy strategy for treating cancer patients with advanced disease. This approach involves utilizing DNA vaccines tailored to target mutations present within the patients' own tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alberta Cancer Foundation
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Funding January 23, 2024
Details:
Under the terms of the research and collaboration agreement, Lilly and Entos have agreed to multiple programs focused on the development of proteo-lipid vehicles (PLV) for delivery of therapeutic cargo supplied by Lilly to targets in the central and peripheral nervous systems.
Lead Product(s): Nucleic acid-based Therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $450.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration January 06, 2022
Details:
Under the terms of the agreement, Entos will use its Fusogenix nucleic acid delivery system to specially formulate BioMarin products directed at multiple undisclosed genetic disease indications.
Lead Product(s): Fusogenix-formulated Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BioMarin Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 15, 2021
Details:
Entos developed a Fusogenix DNA vaccine called Covigenix, that in preclinical studies, induces a strong neutralizing antibody response plus a potent and balanced T cell response against SARS-CoV-2, the virus that causes COVID-19.
Lead Product(s): Covigenix
Therapeutic Area: Infections and Infectious Diseases Product Name: Covigenix
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: NRC IRAP
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 23, 2020
Details:
Company announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine (Covigenix) from its prototyping program launched at the onset of the global COVID-19 pandemic.
Lead Product(s): Fusogenix DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Canadian Institutes of Health Research (CIHR)
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Funding June 25, 2020
Details:
Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery.
Lead Product(s): Covigenix
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: GE Healthcare Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
Details:
This partnership will combine the Entos Fusogenix DNA delivery technology with optimized COVID-19 epitopes from EpiVax to generate a highly effective immune response against the novel coronavirus.
Lead Product(s): Fusogenix
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: EpiVax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 28, 2020
Details:
The vaccine payload will be plasmid DNA encoding multiple antigens from key SARS-CoV-2 proteins to promote maximum protection.
Lead Product(s): Fusogenix DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
